Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,267 across all filing types
Latest filing 2019-08-09 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, the Company is intimating the request received relating to Loss of share certificate and issue of duplicate share certificate ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the loss of share certificates and the request for issuance of duplicate certificates. It references compliance with SEBI Listing Obligations and Disclosure Requirements but does not contain financial data, management discussion, or report content. The document is an official notification related to share certificates, which fits best under Regulatory Filings (RNS) as it is a regulatory announcement without financial statements or report content. The document length is short (2092 characters), and it is not an announcement of a report publication or a financial report itself.
2019-08-09 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed report of voting results from the 40th Annual General Meeting (AGM) of AstraZeneca Pharma India Ltd. held on August 7, 2019. It includes resolution-wise combined results of remote e-voting and ballot, with detailed voting statistics for each resolution, including promoter and public votes, percentages, and pass/fail status. The document references SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 44, which pertains to disclosure of voting results. The content is focused on the official announcement of voting outcomes rather than the AGM presentation materials or proxy solicitation. The length and detail confirm it is not a brief announcement but a full disclosure of voting results. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2019-08-09 English
We wish to inform you that at the Company's Annual General Meeting held on August 7, 2019, the Shareholders have approved the appointment of Mr. Narayan K Seshadri (DIN: 00053563) as Independent ....
Board/Management Information Classification · 100% confidence The document is a letter addressed to stock exchanges announcing the appointment of Mr. Narayan K Seshadri as an Independent Director at the Annual General Meeting held on August 7, 2019. It includes a brief profile of the appointee and requests the exchanges to take the information on record. There are no financial statements, audit details, or other report contents. The document is an announcement of a board/management change rather than a full report or presentation. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on the appointment, confirming it is not a report or presentation but a management change announcement.
2019-08-08 English
Reappointment
Board/Management Information Classification · 100% confidence The document is a letter addressed to stock exchanges announcing the appointment of Mr. Narayan K Seshadri as an Independent Director at the Annual General Meeting held on August 7, 2019. It includes a brief profile of the appointee and confirms shareholder approval of the appointment. There are no financial statements, earnings data, or detailed management discussion. The content is focused on management/board changes. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 2834 characters, which is consistent with a typical management change announcement rather than a full report or presentation.
2019-08-08 English
In relation to the 40th Annual General Meeting of the Company held on August 7, 2019, we enclose the report of Scrutinizer dated August 8, 2019, as required Section 108 of the Companies ....
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'SCRUTINIZER'S REPORT' and references Sections 108 & 109 of the Companies Act, 2013, which relate to voting procedures at company meetings. It details the voting results of resolutions proposed at the 40th Annual General Meeting (AGM) of AstraZeneca Pharma India Limited held in August 2019. The report includes vote counts for ordinary and special business items, such as adoption of financial statements, appointment and re-appointment of directors, and ratification of auditor remuneration. The content is focused on the official results of shareholder voting at the AGM, including remote e-voting and polling paper votes. There is no financial data or management discussion, only the voting results and procedural details. Therefore, this document is a Declaration of Voting Results & Voting Rights Announcement (DVA).
2019-08-08 English
In relation to the 40th Annual General Meeting of the Company held on August 7, 2019, we enclose the brief proceedings as required under Regulation 30, Part A of Schedule III of the SEBI ....
Regulatory Filings Classification · 80% confidence The document text is mostly unreadable or in a non-Latin script, with many placeholders for omitted pictures and tables. There are no clear indications of financial data, regulatory bodies, report titles, or fiscal periods. The length is 4465 characters, which is relatively short. The content appears to be a scanned or image-based document with minimal textual information. There is no evidence of it being a full financial report, earnings release, or any specific filing type. Given the lack of clear content and the presence of images and tables, it is most consistent with a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2019-08-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.